BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/18/2021 6:54:27 AM | Browse: 731 | Download: 1137
 |
Received |
|
2020-12-24 14:02 |
 |
Peer-Review Started |
|
2020-12-24 14:04 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2021-01-18 03:43 |
 |
Revised |
|
2021-02-19 13:25 |
 |
Second Decision |
|
2021-03-11 13:20 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2021-03-12 00:49 |
 |
Articles in Press |
|
2021-03-12 00:49 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2021-03-18 02:29 |
 |
Publish the Manuscript Online |
|
2021-03-18 06:54 |
ISSN |
2220-315x (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Neurosciences |
Manuscript Type |
Retrospective Study |
Article Title |
Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy
|
Manuscript Source |
Invited Manuscript |
All Author List |
Serdar Kabataş, Erdinç Civelek, Necati Kaplan, Eyüp Can Savrunlu, Gülseli Berivan Sezen, Mourat Chasan, Halil Can, Ali Genç, Yener Akyuva, Osman Boyalı, Furkan Diren and Erdal Karaoz |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Serdar Kabataş, MD, PhD, Chairman, Full Professor, Department of Neurosurgery, University of Health Sciences, Gaziosmanpaşa Training and Research Hospital, Karayolları Mahallesi, Osmanbey Caddesi 616, İstanbul 34255, Türkiye. kabatasserdar@gmail.com |
Key Words |
Hypoxic-ischemic encephalopathy; Stem cell; Transplantation; Wharton's jelly |
Core Tip |
Occurring due to the disruption of oxygen supply to the brain, hypoxic-ischemic encephalopathy is associated with substantial rates of morbidity and mortality. In addition to supportive therapy and symptomatic treatment, research on the treatment of hypoxic-ischemic encephalopathy has focused new therapautic strategies as stem cell therapy. This multi-center and open-label phase I study was performed to investigate the safety and preliminary efficacy of multiple triple-route Wharton’s Jelly-Derived Mesenchymal Stem Cells administrations. The patients included in this study also had improvement in modified ashworth scores, Functional Independence Measure scores over the course of a year, indicating long-term impact on brain functions. |
Publish Date |
2021-03-18 06:54 |
Citation |
Kabataş S, Civelek E, Kaplan N, Savrunlu EC, Sezen GB, Chasan M, Can H, Genç A, Akyuva Y, Boyalı O, Diren F, Karaoz E. Phase I study on the safety and preliminary efficacy of allogeneic mesenchymal stem cells in hypoxic-ischemic encephalopathy. World J Exp Med 2021; 11(2): 17-29 |
URL |
https://www.wjgnet.com/2220-315x/full/v11/i2/17.htm |
DOI |
https://dx.doi.org/10.5493/wjem.v11.i2.17 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345